Radiotherapy combination opportunities leveraging immunity for the next oncology practice.

Details

Serval ID
serval:BIB_558CD2425591
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Radiotherapy combination opportunities leveraging immunity for the next oncology practice.
Journal
CA: a cancer journal for clinicians
Author(s)
Herrera F.G., Bourhis J., Coukos G.
ISSN
1542-4863 (Electronic)
ISSN-L
0007-9235
Publication state
Published
Issued date
01/2017
Peer-reviewed
Oui
Volume
67
Number
1
Pages
65-85
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Approximately one-half of patients with newly diagnosed cancer and many patients with persistent or recurrent tumors receive radiotherapy (RT), with the explicit goal of eliminating tumors through direct killing. The current RT dose and schedule regimens have been empirically developed. Although early clinical studies revealed that RT could provoke important responses not only at the site of treatment but also on remote, nonirradiated tumor deposits-the so-called "abscopal effect"- the underlying mechanisms were poorly understood and were not therapeutically exploited. Recent work has elucidated the immune mechanisms underlying these effects and has paved the way for developing combinations of RT with immune therapy. In the wake of recent therapeutic breakthroughs in the field of immunotherapy, rational combinations of immunotherapy with RT could profoundly change the standard of care for many tumor types in the next decade. Thus, a deep understanding of the immunologic effects of RT is urgently needed to design the next generation of therapeutic combinations. Here, the authors review the immune mechanisms of tumor radiation and summarize the preclinical and clinical evidence on immunotherapy-RT combinations. Furthermore, a framework is provided for the practicing clinician and the clinician investigator to guide the development of novel combinations to more rapidly advance this important field. CA Cancer J Clin 2017;67:65-85. © 2016 American Cancer Society.

Keywords
Animals, Antigens, Neoplasm/immunology, Combined Modality Therapy, Humans, Immunotherapy/methods, Neoplasm Metastasis/immunology, Neoplasm Metastasis/radiotherapy, Neoplasms/immunology, Neoplasms/radiotherapy, Radiotherapy Dosage
Pubmed
Create date
16/09/2016 19:48
Last modification date
20/08/2019 15:10
Usage data